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Abstract
There is a pressing need for methods to define the functional relevance of genetic alterations identified by next-generation
sequencing of cancer specimens. We developed new approaches to efficiently construct full-length cDNA libraries from
small amounts of total RNA, screen for transforming and resistance phenotypes, and deconvolute by next-generation
sequencing. Using this platform, we screened a panel of cDNA libraries from primary specimens and cell lines in cytokine-
dependent murine Ba/F3 cells. We demonstrate that cDNA library-based screening can efficiently identify DNA and RNA
alterations that confer either cytokine-independent proliferation or resistance to targeted inhibitors, including RNA
alterations and intergenic fusions. Using barcoded next-generation sequencing, we simultaneously deconvoluted cytokine-
independent clones recovered after transduction of 21 cDNA libraries. This approach identified multiple gain-of-function
alleles, including KRAS G12D, NRAS Q61K and an activating splice variant of ERBB2. This approach has broad applicability for
identifying transcripts that confer proliferation, resistance and other phenotypes in vitro and potentially in vivo.
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Introduction
Thousands of somatic variants have recently been catalogued
across multiple cancer types. However, the functional relevance of
nearly all of these variant alleles remains undefined and only a
small minority are likely to contribute to malignant phenotypes.
Thus, approaches are broadly needed to distinguish which of the
genetic variants present in both coding and noncoding RNA have
functional relevance, and may therefore represent therapeutic
targets [1].
Inhibition of oncogene function can induce cell death and
tumor regression across a variety of cancers but is almost
invariably associated with the selection of resistant clones. Multiple
genetic and epigenetic mechanisms can mediate resistance to
targeted inhibitors, including mutation of the therapeutic target,
activation of downstream signaling pathways and upregulation of
orthogonal pathways. Similar to the identification of oncogenes,
delineating the multiple possible mechanisms of resistance to
targeted inhibitors can be labor intensive and has primarily
involved biased approaches that only interrogate protein-coding
genes [2].
The development of methods for cloning full-length cDNA [3]
and constructing cDNA libraries [4] in the early 1980s led to a
series of phenotype-based screens that broadly interrogated the
transcriptome. For example, the Rennick laboratory identified a
cDNA for human GM-CSF by transfecting cDNA libraries
derived from activated human T-cells into COS-7 monkey cells
[5]. The Nolan laboratory used Ba/F3 cells to isolate clones that
expressed selectable markers like hCD2 or hIL3R after retroviral
transduction of cDNA libraries [6]. Ba/F3 cells are murine
hematopoietic cells that are absolutely dependent on IL3 for
survival. Expression of some oncogene transcripts can substitute
for IL3 signaling, allowing for the selection of monoclonal
populations that proliferate in the absence of IL3.
cDNA libraries have also been used to identify new oncogenes
from tumor cell lines and primary samples. In 1994, Chan et al.
identified a novel RAS superfamily member by screening an
ovarian cancer cell line cDNA library in 3T3 cells. Nearly fifteen
years later, the Mano laboratory used essentially the same protocol
to identify the EML4-ALK fusion from a lung cancer sample [7].
We previously discovered a mutant allele of the CRLF2 cytokine
receptor by screening cDNA libraries generated from primary
acute lymphoblastic leukemias (ALL), which multiple groups
concurrently identified as an important oncogene in poor-risk ALL
[8,9].
Screens of cDNA can identify alterations present within exonic
DNA as well as splice alterations, RNA editing events and
noncoding RNAs. However, standard approaches for generating
and screening high-quality cDNA libraries have multiple short-
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precludes the use of most primary tumor specimens. Second, first-
strand synthesis may prematurely abort and thereby generate
truncated cDNA that are not present within the sample. Third, the
isolation and analysis of individual clones with the desired
phenotype can be very cumbersome. Finally, target cells that
have a background rate of spontaneous transformation (e.g. 3T3)
can generate multiple false positive clones, further reducing the
efficiency of cDNA library screening.
We developed new methods for efficiently generating high-
quality libraries of full-length cDNA using #1 mg total RNA. We
screened a panel of primary specimen and cell line libraries in Ba/
F3 cells to identify transcripts with either DNA or RNA alterations
that could substitute for IL3 signaling. To deconvolute the
integrated cDNA from pools of clones, we developed methods
for next-generation sequencing and bioinformatic analysis that
greatly improve the efficiency of cDNA library-based screening.
These approaches can be applied to screen both primary and
immortalized samples for a variety of phenotypes.
Results and Discussion
To generate high-quality, full-length cDNA libraries, we created
a ‘Full length-att’ protocol that hybridizes the In-Fusion
SMARTer Directional cDNA Library Construction Kit (Clon-
tech) with recombinase reactions (Invitrogen) for shuttling between
vectors (Figure S1). We perform quality control of these libraries in
three steps. First, libraries are transformed into E. coli to confirm
the presence of $10
7 clones per library. Second, restriction
enzyme digestion of each library is performed to demonstrate
clonal heterogeneity (Figure S1). Third, we developed quantitative
PCR (qPCR) approaches using primers that amplify the 59 region
of housekeeping genes to confirm that similar frequencies of long
(e.g. REV3L, 10719 bp) and short (e.g. GAPDH: 1401 bp) full-
length cDNAs are present (Figure S1). We generate libraries in
medium-throughput fashion (i.e., batches of 12) and screen for IL3-
independent growth and drug resistance phenotypes in Ba/F3
cells, as previously performed [10].
To validate this approach, we screened cDNA libraries
generated from the lung cancer cell lines H3122 and H2228
(Figure 1), which both harbor EML4-ALK fusions. All IL3-
independent Ba/F3 clones recovered after transduction of both
libraries harbored full-length EML4-ALK and were sensitive to
the ALK inhibitor crizotinib (LD99,1 mM). Multiple independent
EML4-ALK transcripts were recovered from both libraries, based
on the presence of different lengths of 59 untranslated region
(UTR), which results from variable elongation past the translation
start site during first-strand cDNA synthesis (Figure 1A). Two
distinct EML4-ALK fusion transcripts were identified from
H2228, which differed based on alternate splicing of exon 6
(Figure 1A). Thus, this approach can efficiently recover multiple
gain-of-function transcripts from the same tumor specimen.
To identify an unknown translocation fusion partner, we
screened a cDNA library isolated from a biopsy of a primary
anaplastic large cell lymphoma (ALCL) that expressed the ALK
oncoprotein but did not have the common NPM-ALK rearrange-
ment (Figure 2). We recovered multiple Ba/F3 clones that all
contained and expressed a full-length ATIC-ALK fusion transcript
(Figure 2B–C), which was previously described in a small subset of
ALCLs [11]. We isolated 96 IL3-independent Ba/F3 clones after
transduction of this library and tested the effects of the specific
ALK inhibitor TAE684 on proliferation. Of the 96 clones, only
clone D3 was unaffected by 1 mM TAE684 (Figure 2D).
Sequencing of the integrated cDNA within D3 identified a full-
length STAT5B transcript that harbored a K70N mutation in the
N-terminal region (Figure 2E). Thus, clone D3 had acquired
ALK-independent proliferation in the absence of IL3.
We also utilized cDNA library screening to recover alleles that
confer resistance to targeted inhibitors. First, we generated the
PC9-ER cell line by culturing PC9 lung cancer cells, which express
the transforming EGFR delE745-A750 allele, in the presence of
escalating doses of the EGFR inhibitor erlotinib (Figure 3A). As
previously described, this resulted in subclonal outgrowth of PC9
cells harboring the gatekeeper mutation T790M, which can be
difficult to discern by Sanger sequencing (Figure 3B) [12].
Screening of a cDNA library generated from PC9-ER in Ba/F3
cells resulted in multiple full-length clones that harbored EGFR
with both delE745-A750 and T790M (Figure 3C) and were
sensitive to the mutant-selective EGFR inhibitor WZ4002
(LD99,1 mM) [13].
Transduction of Ba/F3 cells at a high multiplicity of infection
(MOI) allows for screening of .10
7 transcripts in medium-
throughput fashion, but the IL3-independent Ba/F3 clones
typically harbor 5–15 distinct cDNA inserts (Figure 1). To
functionally deconvolute inserts from IL3-independent Ba/F3
clones, we developed methods for insert identification by next-
generation sequencing. To test this strategy, we generated 21
cDNA libraries from primary specimens and cell lines and
transduced each library into 5610
6 Ba/F3 cells. After withdrawal
of IL3, proliferating clones were subjected to PCR amplification of
integrated cDNA, followed by barcoding by library, pooling and
sequencing on the SOLiD 4 platform. Approximately 18 Gbp of
sequence data was mapped to the human reference genome
(hg18). As genes with functional relevance are typically present in
multiple clones with different 59 UTRs (Figure 1), we developed a
bioinformatic pipeline for the detection of attB fusion sequences
and precisely mapped the genomic coordinates of the integrated
cDNA.
Among the 21 libraries were two positive controls, which were
known to harbor activating RAS family alleles. Library transduc-
tion followed by PCR amplification of integrated cDNA from IL3-
independent clones and next-generation sequencing successfully
identified both KRAS G12V from the small cell lung carcinoma
line SHP-77 and NRAS Q61K from the melanoma cell line SK-
MEL-23 (Figure 4). From the latter, 12 independent fusions of attB
sequence with the 59 UTR of NRAS, representing full-length
transcripts, were recovered in amplified fragments (Figure 4C).
NRAS was also the most abundant transcript in amplified
fragments from the SK-MEL-23 library, with a fragments per
kilobase of exon per million fragments mapped (FPKM) value of
61516. The next 7 most abundantly recovered genes (PKM2,
TKT, ACTG1, RPL11, AP4M1, OAZ2, IMPDH2) are all
housekeeping genes and were present at FPKM values between
10165–14711. From amplified fragments recovered from the
SHP-77 library, KRAS was the 5
th most abundant transcript
(FPKM 30645), behind the non-coding transcript GAS5 (FPKM
56640) and the genes UBE2V2, CHMP5, RPL18 and RPL19
(FPKM 36338–48842). No variants were present in the coding
sequence of any of these 4 genes. Thus, the identification of
mutated transcripts expressed at high FPKM can highlight driver
alterations with this method.
Next-generation sequencing-based deconvolution identified a
splice variant of ERBB2 that lacks exon 16 (ERBB2D16) from the
breast carcinoma line HCC1569 (Figure 5). Expression of
ERBB2D16 results in resistance to the ERBB2-specific monoclonal
antibody trastuzumab and constitutive activation of SRC [14].
ERBB2D16 was also recovered from the melanoma cell lines
MeWo and 70 W (Figure 5C). Transcripts isolated from each line
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and confirming that they derived from independent lines
(Figure 5C). Although ERBB2D16 was detectable in MeWo and
70 W cells, it was expressed at levels 10–1000-fold lower than in
the trastuzumab-resistant breast cancer cell lines HCC1569 and
BT474 [14] by qPCR (Figure 5D, 5E). ERBB2D16 was not among
the top 50 transcripts recovered by next-generation sequencing
(based on FPKM). Finally, neither melanoma MeWo nor 70 W
was sensitive to the EGFR/ERBB2 inhibitor lapatinib (Figure 5B).
This suggests that ERBB2D16 is not a primary driver of
proliferation in MeWo and 70 W cells but could potentially
compensate upon targeted inhibition of other pathways.
In conclusion, cDNA library screening with deconvolution by
next-generation sequencing can efficiently identify fusions, intra-
genic alterations and splice variants from primary specimens and
cell lines in medium throughput. These approaches are amenable
to screens both in vitro and potentially in vivo, either to agnostically
interrogate cDNA libraries or to identify individual transcripts
within selected pools for proliferation, resistance and other
phenotypes.
Methods
Ethics statement
All specimens were acquired from patients at the Dana-Farber
Cancer Institute. This study was approved by the Dana-Farber
Cancer Institute Institutional Review Board (DFCI IRB #01-026).
No research was conducted outside of the United States. All
participants provided written consent under the aforementioned
protocol.
Cell lines and media
Ba/F3 cells were obtained from RIKEN. SHP-77, HCC1569
and BT-474 were obtained from ATCC. H3122, H2228 and PC9
were previously reported [15]. MeWo, 70 W and SK-MEL-23
were previously reported [16,17] and were a kind gift of Dr. David
Fisher (Massachusetts General Hospital). All cells were cultured
according to published conditions. Immunohistochemistry for
ALK was performed as previously described [18].
Figure 1. cDNA library screening identifies EML4-ALK. A. Screening of a library generated from H2228 cells generated 16 clones with distinct
patterns of integrated cDNA. All clones contained one of two EML4-ALK transcripts that differed based on splicing of exon 6 and the length of the 59
untranslated region, as indicated by the most 59 nucleotide fused to the attB sequence. l indicates size ladder. B. Screening of a library generated
from H3122 cells generated Ba/F3 clones isolated at the indicated time point after withdrawal of IL3. PCR is shown using primers that amplify
integrated cDNA. C. PCR amplification from eight clones generated from the H3122 library with different patterns of integrated cDNA. Five distinct
EML4-ALK transcripts were identified based on differences in the length of the 59 untranslated region, as in A.
doi:10.1371/journal.pone.0049201.g001
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construction
For construction of full-length cDNA libraries, total RNA was
purified using TRIzol reagent (invitrogen) or the RNeasy Mini Kit
(Qiagen) followed by DNase I treatment according to the
manufacturer’s instructions. #1 ug total RNA was used for cDNA
library construction using a ‘‘Full length-att’’ approach that
hybridizes the In-Fusion SMARTer Directional cDNA Library
Construction Kit (Clontech) with recombinase reactions (Invitro-
gen) for shuttling between vectors. The In-Fusion SMARTer
Directional cDNA Library methodology was performed with the
following modifications. PCR primers were designed to incorpo-
rate attB1 recombinase recognition sites during amplification of
the SMARTer first-strand cDNA:
attB1_forward: 59-GGGGACAACTTTGTACAAAAAAGTT-
GGAAGCAGTGGTATCAACGCAGAG-39
Figure 2. cDNA library screening identified an ALK translocation partner and resistance allele. A. Immunohistochemistry using an
antibody against ALK and karyotype of the anaplastic large cell lymphoma specimen 421. B. Multiple IL3-independent clones were recovered from
screening of the cDNA library generated from 421, all of which contained ALK cDNA using primers within the flanking attB sites or within ALK itself. C.
Immunoblot using antibody against ALK demonstrates ATIC-ALK expression in multiple clones but not in wild-type Ba/F3 cells. D. Effect on
proliferation of 96 individual clones recovered from the 421 library with TAE684 300 nM, quantified using the ATP chemiluminescent agent
CellTiterGlo. E. PCR amplification using the att-f and att-r primers with DNA from clone D3 demonstrates a full-length STAT5B allele that harbored a
G210T (K70N) mutation.
doi:10.1371/journal.pone.0049201.g002
Figure 3. Screening for resistance alleles. A. Selection of PC9 cells in media containing increasing concentrations of erlotinib resulted in the
PC9-ER line, which is unaffected by doses of erlotinib up to 1 mM. B. The IL3-independent Ba/F3 clone 1C8 recovered by cDNA library screening of
PC9-ER cells contains both the Dex19 activating mutation and the T790M mutation in EGFR. C. Sanger sequencing shows that only a small fraction of
EGFR amplified from PC9-ER cells harbors the T790M alteration, in contrast with 1C8.
doi:10.1371/journal.pone.0049201.g003
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GGGTCGGGGTACGATGAGACACCA-39
Long distance-PCR was carried out with PrimeSTAR HS DNA
polymerase (Takara) using the following PCR conditions: 95uC for
1 min, 15 cycles of 98uC for 10 sec, 55uC for 5 sec and 68uC for
10 min. After purification according to the manufacturer’s
instructions, 300 ng of ds cDNA was cloned into 300 ng of
pDONR222 vector with Gateway BP Clonase II enzyme mix
(Invitrogen). The retroviral Gateway destination vector
pMSCVpuroATT was constructed by inserting Reading Frame
Cassette A into the retroviral expression vector pMSCVpuro
(Clontech) using the Gateway Vector Conversion System (Invitro-
gen). Libraries were transferred from the pDONR222 backbone to
pMSCVpuroATT using Gateway LR Clonase (Invitrogen). After
Figure 4. Deep sequencing deconvolution of multiple cDNA inserts. A. Screening of the SK-MEL-23 melanoma cell line results in multiple
clones with different patterns of cDNA inserts (upper) that all harbor NRAS based on an NRAS specific PCR (lower). B. The mutant NRAS allele harbors
an A434T (G60G) and C435A (Q61K) dinucleotide substitution (underlined by thick black bar) that is present as 100% of sequence within a BaF3
transformant and as 50% or less in the SK-MEL-23 cDNA, plasmid acceptor library and retroviral library. C. Deep sequencing identified 12 distinct
fusion sequences between the attB (black triangle) and 59 UTR of NRAS from the SK-MEL-23 library. The number of individual reads for each of the
sequences is provided. D. A subset of approximately 90,000 reads across the NRAS dinucleotide substitution are shown. The sequence is on the
genomic negative strand and thus reversed from C. The C435A (GRT shown on the positive strand) substitution that results in Q61K is between the
hashed marks. Gray reads have the paired-end on the same exon while brown reads have the paired-end on the next exon.
doi:10.1371/journal.pone.0049201.g004
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coli (Invitrogen), each pMSCVpuroATT library was cultured at
30uC for 16 hour and purified with thePureLink HQ Midi
Plasmid Purification Kit (invitrogen), as described [10].
For libraries constructed with the CloneMiner II cDNA
construction kit (Invitrogen), high-quality mRNA was isolated
from total RNA with the FastTrack2.0 mRNA Isolation Kit
(Invitrogen) according to the manufacturer’s instructions. Up to
5 mg mRNA was used according to the manufacturer’s instruc-
tions. Recombination of attB-flanked cDNA was performed into
the attP-containing pDONR222 vector to create a high titer entry
library. This library was then transferred into pMSCVpuroATT,
as above.
Library quality control
All libraries were confirmed to contain $10
7 clones by
transformation into E.coli and heterogeneity was confirmed by
BsrGI digest (Figure S1). Adequate representation of long full-
length cDNA was confirmed within cDNA libraries using qPCR
with primers that amplified the 59 region of long (TFRC: 5241 bp,
Figure 5. Recovery of a transforming ERRB2 splice variant. A. cDNA library screening of the melanoma cell lines 70 W (a sub-line of the
MeWo) and HCC1569 resulted in IL3 independent Ba/F3 clones that contained ERBB2D16. B. Relative proliferation quantified using the ATP
chemiluminescent agent CellTiterGlo. C. cDNA transcripts recovered from screening of MeWo, HCC1569 and 70 W cell lines. All of the transcripts
lacked amino acids 2137–2184 that comprise exon 6. D. Expression of ERBB2 cDNA containing exon 16 using specific primers. Error bars indicate
standard deviation. E. Expression of ERBB2D16 cDNA using specific primers, including a 59 primer that overlaps exons 15 and 17 so does not amplify
wild-type ERBB2.
doi:10.1371/journal.pone.0049201.g005
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1401 bp, ACTB: 1852 bp) housekeeping genes.
GAPDH-F: 59-GTCAGCCGCATCTTCTTTTG-39;5 9-AC-
GACCAAATCCGTTGACTC-39
ACTB: 59-GATGCAGAAGGAGATCACTGC-39;5 9-
TGATCCACATCTGCTGGAAG-39
TFRC #1: 59-AGTGATTGTCAGAGCAGGGAAA-39;5 9-
CCCAGATGAGCATGTCCAAA-39
TFRC #2: 59-GAGTGTGAGAGACTGGCAGGAA-39;5 9-
CGGTGAAGTCTGTGCTGTCC-39
POLQ #1: 59-GGCAGCACCTCTCCATCAA-39;5 9-
TCATCCACAACCACCATTCC-39
POLQ #2: 59-TGTGGCTTCCTGGTTGAATG-39;5 9-
GGGCTCAAATTCCCTCACAA-39
REV3L #1: 59-AAGTGGATGCTGTAGCTGCTGA-39;5 9-
GCCGTTGCTTTTCATCTTCC-39
REV3L #2: 59-TCTGGCTGCTGTCAAGTTCC-39;5 9-
TCATCTTGTTCCCACCGAAA-39
Retroviral cDNA library screening
293T cells (7610
5 cells in 2 mL of Dulbecco’s Modified Eagle
Medium supplemented with 10% fetal calf serum) were inoculated
into a single well of a 6-well plate. After 24 hours, 3 mgo f
pMSCVpuroATT cDNA library and 1 mg of pEcoPack vector
were co-transfected into 293T cells with 10 mL of Lipofecta-
mine2000 transfection reagent (invitrogen) and 500 mL of Opti-
MEM I Reduced Serum Media (Invitrogen). On the following
day, 2.5 mL of fresh medium was added to the cells. After an
additional day, the supernatant was passed through a 0.45 mm
filter. Before the infection, sub-confluent Ba/F3 cells were diluted
100-fold and then cultured for 3 days in log-growth phase using
RPMI-1640 medium supplemented with 10% FCS, 0.5 ng/mL of
mouse IL3 (Prospec), penicillin and streptomycin. 2.5 mL of viral
supernatant was applied to 5610
6 Ba/F3 cells in 2.5 mL, along
with 16 mg/mL of polybrene, 10 mM of HEPES-HCL and
0.5 ng/mL of mouse IL3 in a single well of a 6-well plate. The
cells were centrifuged at 2500 rpm for 90 min at 37uC. Infected
cells were washed once with media containing IL3 on the next day
and 1 mg/mL of puromycin was added to the cells 2 days after
infection. 48 hours later (4 days after infection), the cells were
washed 3 times and 3–4610
4 cells were plated into a 96-well plate
with puromycin containing media without mouse IL3. After 10–28
days, visible colonies were isolated. Alternatively, cells were
washed 96 hours after infection and transferred to a flask
containing media without IL3. Proliferating cells were visible
21–28 days after infection. In our previous screening [10],
infection involved up to 3–6610
7 Ba/F3 cells at the same density
in multiple plates.
Identification of integrated cDNA
To determine integrated cDNA sequences from IL3-indepen-
dent Ba/F3 clones, genomic DNA was purified using the QIAamp
DNA Blood Mini Kit (Qiagen) and used as template for a step-
down PCR with primers flanking the inserted cDNA sequences:
att-f: 59-TCCTCCCTTTATCCAGCCCTCACTCCTTCTC-
TAGG-39
att-r: 59-CTAAAGCGCATGCTCCAGACTGCCTTGG-
GAAAAGC-39
PCR was conducted with KOD-FX DNA polymerase (Toyobo)
using the following PCR conditions: 94uC for 4 min, 5 cycles of
98uC for 10 sec and 74uC for 8 min, 5 cycles of 98uC for 10 sec
and 72uC for 8 min, 5 cycles of 98uC for 10 sec and 70uC for
8 min, 15 cycles of 98uC for 10 sec and 68uC for 8 min, and 68uC
for 10 min. For the isolation of individual integrants, 25 mLo f
PCR product was separated by agarose gel electrophoresis and
bands were purified from the gel using the QIAquick Gel
Extraction Kit (Qiagen) and sequenced from the 59 end by the
Sanger method (Dana-Farber Cancer Institute Molecular Biology
Core Facility).
For deep sequencing, PCR products amplified from indepen-
dent Ba/F3 transformants within the same cDNA library were
mixed at equimolar amounts (1–10 mL) and purified using the
QIAquick PCR Purification Kit (Qiagen).
Establishment of erlotinib resistant PC-9 cell line and
inhibitor assays
PC9 cells were initially treated with 1 nM erlotinib and the
concentration was increased to 3 nM, 10 nM, 100 nM and 1 mM
as clones emerged over the course of approximately 2 months. To
confirm resistance to erlotinib among the surviving PC9-ER cells,
a dose response study was performed using the CellTiter-GloH
Luminescent Cell Viability Assay (Promega) and read by the 2104
EnVisionH Multilabel Reader (PerkinElmer) after 48 hour treat-
ment. Dose response to lapatinib was also quantified using
CellTiter-GloH after 48 hour treatment, as above.
SOLiD library construction and sequencing
A sequencing library was generated from PCR products which
were amplified from transfected DNA from each of 21 specimens.
An average of approximately 10 IL3-independent BaF3 clones
were derived from each screened library. We estimated that cDNA
inserts would average 2 kb and that each BaF3 clone contains an
average of 7 inserts, for a total of approximately 3610
6 bases of
cDNA sequence PCR amplified from all 21 specimens. Sequenc-
ing of 10
10 bases would thus generate greater than 3000-fold mean
coverage which may be necessary to confidently recover larger
and/or repetitive cDNA with lower PCR amplification efficiency.
The method used to generate the libraries is described in the
Applied Biosystems SOLiD 4 Library Preparation guide. Briefly,
for each library, the PCR products were concatatenated by
ligation and then sheared. An adaptor was ligated to each end of
each sheared fragment. One of the two adaptors contained a
barcode sequence, which was unique for each library. Each library
was amplified by 6–8 cycles of PCR. After quantification, the
libraries were mixed in equimolar amounts and then subjected to
emulsion PCR. The beads resulting from the emulsion were
sequenced from each end - 75 bases from one end and 35 bases
from the other end, on 4 lanes using an Applied Biosystems 5500
sequencer. The libraries were binned according to barcode
sequence.
Mapping and counting
Sequence data were mapped to the human reference genome,
hg18, using the Genomic Resequencing and Whole Transcrip-
tome Mapping modules contained in Lifescope 2.5 (Applied
Biosystems.) The Lifescope 2.5 Exon Counts module was used in
conjunction with a custom Python script to generate gene-level
data, indentifying those transcripts which were present at a high
level in each sample.
Gateway Junction Detection
To identify the precise genomic coordinates of integrated
cDNA, a pipeline for the detection of gateway fusion sequences
was developed. Individual reads containing a piece of the Gateway
attB sequence (59-TTGTACAAAAAAGTTGG9-39) were pulled
from the Whole Transcriptome mapped data. Reads were selected
if their color-space sequence matched the color-space sequence of
New Methods for cDNA Library Screening
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reverse (59-G0101200000113110-39). A python script was devel-
oped to identify and report the precise coordinate of the gateway
fusion for each selected read, taking into account forward vs.
reverse strandedness, clipped mappings, and mappings crossing
exon junctions. These gateway fusion coordinates were collected
and reported at the gene level for each of the 21 multiplexed
samples.
Variant Analyses
Single Nucleotide Variants were called using DiBayes (Applied
Biosystems) and annotated with information including exonic
context (using RefSeq), known polymorphisms (using DBSNP
130), amino acid consequence, and frequency and quality of reads
supporting each variant. Fusions genes were detected using the
output of Lifescope’s Splice Finder module and annotated against
RefSeq using a Python script.
Supporting Information
Figure S1 Full length-att method for library construc-
tion. A. cDNA was generated from PC9 and K562 cells using the
In-Fusion SMARTer Kit and using the full length-att method,
which modifies the former approach using the attB1_forward and
attB2_reverse primers for first strand synthesis. cDNA was
separated by agarose gel electrophoresis. l indicates size ladder.
B. Size fractionation of cDNA from PC9 and K562 cells
generated using the full length-att method. C. BsrG1 digest of
pDONR222 plasmids harboring cDNA from the K562 library
generated using the full length-att method. D. Comparison
between methodologies. Negative and positive controls are from
the CloneMiner II kit (Invitrogen). The PC9ER library is
described in Figure 3. CFUs indicates colony forming units.
(EPS)
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